Arch Biopartners Inc. (ARCH.V)
CAD 1.7
(-2.86%)
CAD 1.7
(-2.86%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 1.17 Million CAD | 88.4% |
| 2022 | 621.64 Thousand CAD | -76.7% |
| 2021 | 2.66 Million CAD | 259.94% |
| 2020 | 741.3 Thousand CAD | 30.52% |
| 2019 | 567.98 Thousand CAD | -15.57% |
| 2018 | 672.69 Thousand CAD | 890.16% |
| 2017 | 67.93 Thousand CAD | -70.08% |
| 2016 | 227.03 Thousand CAD | -65.05% |
| 2015 | 649.5 Thousand CAD | 60.06% |
| 2014 | 405.79 Thousand CAD | 1001.91% |
| 2013 | 36.82 Thousand CAD | -60.75% |
| 2012 | 93.81 Thousand CAD | -57.75% |
| 2011 | 222.04 Thousand CAD | -58.52% |
| 2010 | 535.28 Thousand CAD | 33355.19% |
| 2009 | 1600.00 CAD | -99.8% |
| 2008 | 797.32 Thousand CAD | -16.98% |
| 2007 | 960.41 Thousand CAD | 0.74% |
| 2006 | 953.38 Thousand CAD | -17.63% |
| 2005 | 1.15 Million CAD | -15.87% |
| 2004 | 1.37 Million CAD | -16.02% |
| 2003 | 1.63 Million CAD | 2668.41% |
| 2002 | 59.18 Thousand CAD | -16.12% |
| 2001 | 70.55 Thousand CAD | -97.02% |
| 2000 | 2.36 Million CAD | 87.01% |
| 1999 | 1.26 Million CAD | 575.79% |
| 1998 | 187.16 Thousand CAD | -47.71% |
| 1997 | 357.96 Thousand CAD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q3 | 1.53 Million CAD | -13.98% |
| 2024 Q2 | 1.78 Million CAD | 181.13% |
| 2024 Q1 | 636.47 Thousand CAD | -45.65% |
| 2023 Q4 | 1.17 Million CAD | -17.32% |
| 2023 FY | 1.17 Million CAD | 88.4% |
| 2023 Q2 | 3.69 Million CAD | 414.26% |
| 2023 Q1 | 718.12 Thousand CAD | 15.52% |
| 2023 Q3 | 1.41 Million CAD | -61.65% |
| 2022 Q1 | 1.51 Million CAD | -43.24% |
| 2022 Q4 | 621.64 Thousand CAD | -66.36% |
| 2022 FY | 621.64 Thousand CAD | -76.7% |
| 2022 Q2 | 2 Million CAD | 32.17% |
| 2022 Q3 | 1.84 Million CAD | -7.69% |
| 2021 Q1 | 742.1 Thousand CAD | 0.11% |
| 2021 Q2 | 361.56 Thousand CAD | -51.28% |
| 2021 Q3 | 2.7 Million CAD | 646.98% |
| 2021 Q4 | 2.66 Million CAD | -1.21% |
| 2021 FY | 2.66 Million CAD | 259.94% |
| 2020 Q3 | 1.8 Million CAD | 178.85% |
| 2020 FY | 741.3 Thousand CAD | 30.52% |
| 2020 Q1 | 103.51 Thousand CAD | -81.77% |
| 2020 Q2 | 648.25 Thousand CAD | 526.24% |
| 2020 Q4 | 741.3 Thousand CAD | -58.99% |
| 2019 Q2 | 156.5 Thousand CAD | -57.7% |
| 2019 Q4 | 567.98 Thousand CAD | -40.97% |
| 2019 Q3 | 962.15 Thousand CAD | 514.77% |
| 2019 Q1 | 369.98 Thousand CAD | -45.0% |
| 2019 FY | 567.98 Thousand CAD | -15.57% |
| 2018 Q1 | 220.47 Thousand CAD | 224.52% |
| 2018 FY | 672.69 Thousand CAD | 890.16% |
| 2018 Q3 | 1.38 Million CAD | 0.2% |
| 2018 Q2 | 1.38 Million CAD | 527.76% |
| 2018 Q4 | 672.69 Thousand CAD | -51.49% |
| 2017 Q3 | 34.43 Thousand CAD | -88.41% |
| 2017 Q1 | 85.34 Thousand CAD | -62.41% |
| 2017 Q2 | 297.03 Thousand CAD | 248.03% |
| 2017 Q4 | 67.93 Thousand CAD | 97.31% |
| 2017 FY | 67.93 Thousand CAD | -70.08% |
| 2016 Q4 | 227.03 Thousand CAD | -49.28% |
| 2016 Q3 | 447.62 Thousand CAD | 49.21% |
| 2016 Q2 | 299.99 Thousand CAD | -36.67% |
| 2016 Q1 | 473.72 Thousand CAD | -27.06% |
| 2016 FY | 227.03 Thousand CAD | -65.05% |
| 2015 Q3 | 736.08 Thousand CAD | -18.65% |
| 2015 Q4 | 649.5 Thousand CAD | -11.76% |
| 2015 Q1 | 300.68 Thousand CAD | -25.9% |
| 2015 Q2 | 904.84 Thousand CAD | 200.93% |
| 2015 FY | 649.5 Thousand CAD | 60.06% |
| 2014 Q1 | 38.83 Thousand CAD | 5.44% |
| 2014 Q4 | 405.79 Thousand CAD | 101.63% |
| 2014 Q3 | 201.25 Thousand CAD | -31.7% |
| 2014 Q2 | 294.66 Thousand CAD | 658.85% |
| 2014 FY | 405.79 Thousand CAD | 1001.91% |
| 2013 Q4 | 36.82 Thousand CAD | 209.67% |
| 2013 FY | 36.82 Thousand CAD | -60.75% |
| 2013 Q3 | 11.89 Thousand CAD | -24.59% |
| 2013 Q2 | 15.76 Thousand CAD | -57.05% |
| 2013 Q1 | 36.71 Thousand CAD | -60.87% |
| 2012 Q3 | 155.19 Thousand CAD | 66.64% |
| 2012 FY | 93.81 Thousand CAD | -57.75% |
| 2012 Q1 | 138.1 Thousand CAD | -37.8% |
| 2012 Q2 | 93.13 Thousand CAD | -32.56% |
| 2012 Q4 | 93.81 Thousand CAD | -39.55% |
| 2011 Q2 | 374.14 Thousand CAD | -23.14% |
| 2011 FY | 222.04 Thousand CAD | -58.52% |
| 2011 Q3 | 313.79 Thousand CAD | -16.13% |
| 2011 Q1 | 486.75 Thousand CAD | -9.07% |
| 2011 Q4 | 222.04 Thousand CAD | -29.24% |
| 2010 FY | 535.28 Thousand CAD | 33355.19% |
| 2010 Q4 | 535.28 Thousand CAD | -20.27% |
| 2010 Q2 | 97.00 CAD | -93.94% |
| 2010 Q1 | 1600.00 CAD | -86.1% |
| 2010 Q3 | 671.37 Thousand CAD | 692039.18% |
| 2009 FY | 1600.00 CAD | -99.8% |
| 2009 Q1 | 797.32 Thousand CAD | -71.43% |
| 2009 Q2 | 892.1 Thousand CAD | 11.89% |
| 2009 Q4 | 11.51 Thousand CAD | 1044.14% |
| 2009 Q3 | 1006.00 CAD | -99.89% |
| 2008 FY | 797.32 Thousand CAD | -16.98% |
| 2008 Q1 | 960.41 Thousand CAD | -23.73% |
| 2008 Q2 | 1.4 Million CAD | 46.49% |
| 2008 Q3 | 1.53 Million CAD | 8.92% |
| 2008 Q4 | 2.79 Million CAD | 82.1% |
| 2007 Q3 | 765.92 Thousand CAD | -4.19% |
| 2007 Q1 | 953.38 Thousand CAD | 14.58% |
| 2007 Q2 | 799.43 Thousand CAD | -16.15% |
| 2007 FY | 960.41 Thousand CAD | 0.74% |
| 2007 Q4 | 1.25 Million CAD | 64.41% |
| 2006 FY | 953.38 Thousand CAD | -17.63% |
| 2006 Q4 | 832.07 Thousand CAD | 6.12% |
| 2006 Q3 | 784.11 Thousand CAD | 14.11% |
| 2006 Q2 | 687.18 Thousand CAD | -40.63% |
| 2006 Q1 | 1.15 Million CAD | 5.4% |
| 2005 Q4 | 1.09 Million CAD | 24.61% |
| 2005 Q3 | 881.27 Thousand CAD | -17.45% |
| 2005 Q2 | 1.06 Million CAD | -22.41% |
| 2005 Q1 | 1.37 Million CAD | -40.29% |
| 2005 FY | 1.15 Million CAD | -15.87% |
| 2004 Q3 | 2.28 Million CAD | 25.25% |
| 2004 Q1 | 1.63 Million CAD | 2320.72% |
| 2004 Q2 | 1.82 Million CAD | 11.24% |
| 2004 FY | 1.37 Million CAD | -16.02% |
| 2004 Q4 | 2.3 Million CAD | 0.94% |
| 2003 Q4 | 67.68 Thousand CAD | -26.1% |
| 2003 Q3 | 91.58 Thousand CAD | 42.0% |
| 2003 Q2 | 64.49 Thousand CAD | 8.98% |
| 2003 Q1 | 59.18 Thousand CAD | -61.06% |
| 2003 FY | 1.63 Million CAD | 2668.41% |
| 2002 FY | 59.18 Thousand CAD | -16.12% |
| 2002 Q4 | 151.97 Thousand CAD | -3.23% |
| 2002 Q2 | 178.36 Thousand CAD | 152.79% |
| 2002 Q3 | 157.05 Thousand CAD | -11.94% |
| 2002 Q1 | 70.55 Thousand CAD | 0.0% |
| 2001 Q1 | 2.36 Million CAD | 0.0% |
| 2001 Q2 | 2.3 Million CAD | -2.44% |
| 2001 Q3 | 2.06 Million CAD | -10.32% |
| 2001 FY | 70.55 Thousand CAD | -97.02% |
| 2000 FY | 2.36 Million CAD | 87.01% |
| 2000 Q1 | 1.26 Million CAD | 0.0% |
| 1999 Q1 | 187.16 Thousand CAD | -50.65% |
| 1999 FY | 1.26 Million CAD | 575.79% |
| 1998 FY | 187.16 Thousand CAD | -47.71% |
| 1998 Q4 | 379.27 Thousand CAD | 20.51% |
| 1998 Q2 | 342.73 Thousand CAD | 0.0% |
| 1998 Q3 | 314.73 Thousand CAD | -8.17% |
| 1997 FY | 357.96 Thousand CAD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Covalon Technologies Ltd. | 24.9 Million CAD | 95.297% |
| Hemostemix Inc. | 313.76 Thousand CAD | -273.264% |
| Universal Ibogaine Inc. | 6.31 Million CAD | 81.462% |
| Kane Biotech Inc. | 5.68 Million CAD | 79.384% |
| MedMira Inc. | 3.65 Million CAD | 67.929% |
| Marvel Biosciences Corp. | 672.38 Thousand CAD | -74.181% |
| NervGen Pharma Corp. | 13.23 Million CAD | 91.152% |
| XORTX Therapeutics Inc. | 7.21 Million CAD | 83.756% |